UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials

The Lancet global health, 2019-08, Vol.7 (8), p.e1054-e1064

2019

Volltextzugriff (PDF)

A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial

Contraception: X, 2020-01, Vol.2, p.100031-100031, Article 100031

2020

Volltextzugriff (PDF)

PREGNANCIES BY ACTS OF INTERCOURSE WITH VAGINAL PH MODULATOR: RESULTS FROM THE AMPOWER STUDY

Fertility and sterility, 2022-10, Vol.118 (4), p.e47-e47

2022

Volltextzugriff (PDF)

Characterization of Women Who Experienced Urinary Tract Infections in the Phase 3 AMPOWER Trial [A15]

Obstetrics and gynecology (New York. 1953), 2022-05, Vol.139 (1), p.5-5S

2022

Volltextzugriff (PDF)

Continuation rates of two different-sized copper intrauterine devices among nulliparous women: Interim 12-month results of a single-blind, randomised, multicentre trial

EClinicalMedicine, 2022-09, Vol.51, p.101554-101554, Article 101554

2022

Volltextzugriff (PDF)

TIMING OF ON-STUDY PREGNANCIES WITH A VAGINAL pH MODULATOR IN THE PHASE 3 AMPOWER TRIAL

Fertility and sterility, 2021-09, Vol.116 (3), p.e291-e291

2021

Volltextzugriff (PDF)

CHARACTERIZATION OF WOMEN ACCORDING TO THEIR SEXUAL SATISFACTION AFTER TREATMENT WITH THE NOVEL VAGINAL PH REGULATOR (VPR™) DURING THE AMPOWER STUDY

Fertility and sterility, 2020-09, Vol.114 (3), p.e172-e173

2020

Volltextzugriff (PDF)

Genitourinary Side Effects With the Vaginal pH Regulator: Results From AMPOWER [19I]

Obstetrics and gynecology (New York. 1953), 2020-05, Vol.135 (1), p.96-96S

2020

Volltextzugriff (PDF)

Contraceptive efficacy should primarily be measured using life table pregnancy rates

Contraception (Stoneham), 2023-11, Vol.127, p.110140-110140, Article 110140

2023

Volltextzugriff (PDF)

Efficacy and safety of a multipurpose vaginal pH-regulator: results from the phase 3, ampower contraception clinical trial

Fertility and sterility, 2019-09, Vol.112 (3), p.e10-e10

2019

Volltextzugriff (PDF)

Women’s satisfaction with the multipurpose vaginal pH-regulator (MVP-R; Amphora): results from the phase 3 ampower trial

Fertility and sterility, 2019-09, Vol.112 (3), p.e307-e307

2019

Volltextzugriff (PDF)

Sexual Satisfaction Results With the Vaginal pH Modulator From the Phase 3 AMPOWER Study

Journal of sexual medicine, 2022-06, Vol.19 (6), p.975-982

2022

Volltextzugriff (PDF)

Sexual Satisfaction Results with the Vaginal pH Modulator from the Phase 3 AMPOWER Study

Journal of sexual medicine, 2022-06, Vol.19 (6), p.975

2022

Volltextzugriff (PDF)

Efficacy, Safety, and Acceptability of Acidform (Amphora) and Nonoxynol-9 Contraceptive Vaginal Gels [16N]

Obstetrics and gynecology (New York. 1953), 2016-05, Vol.127 (Supplement 1), p.118

2016

Volltextzugriff (PDF)

Perfect-Use Pregnancy Rates With the Vaginal pH Regulator: Efficacy Results From AMPOWER [30I]

Obstetrics and gynecology (New York. 1953), 2020-05, Vol.135 (1), p.99-99S

2020

Volltextzugriff (PDF)

Sexual Satisfaction With the Vaginal pH Regulator: Results From the AMPOWER Clinical Trial [32I]

Obstetrics and gynecology (New York. 1953), 2020-05, Vol.135 (1), p.100-100S

2020

Volltextzugriff (PDF)

Single-Dose, Bioadhesive Clindamycin 2% Gel for Bacterial Vaginosis: A Randomized Controlled Trial

Obstetrics and gynecology (New York. 1953), 2022-06, Vol.139 (6), p.1092-1102

2022

Volltextzugriff (PDF)

Preliminary Efficacy of Topical Sildenafil Cream for the Treatment of Female Sexual Arousal Disorder: A Randomized Controlled Trial

Obstetrics and gynecology (New York. 1953), 2024-08, Vol.144 (2), p.144

2024

Volltextzugriff (PDF)

Spherical Ball-Shaped Intrauterine Device Long-Acting Reversible Contraception: Post-marketing Pharmacovigilance Assessment

European Medical Journal. Reproductive health, 2023-07, p.2-10

2023

Volltextzugriff (PDF)

Successful Postcoital Testing of Ovaprene: An Investigational Non-hormonal Monthly Vaginal Contraceptive

Obstetrical & gynecological survey, 2024-09, Vol.79 (9), p.521-522

2024

Volltextzugriff (PDF)

The use of serum segesterone acetate levels to assess adherence of trial participants with a contraceptive vaginal ring

Contraception (Stoneham), 2022-04, Vol.108, p.61-64

2022

Volltextzugriff (PDF)

Emergency contraception for individuals weighing 80 kg or greater: A randomized trial of 30 mg ulipristal acetate and 1.5 mg or 3.0 mg levonorgestrel

Contraception (Stoneham), 2024-09, Vol.137, p.110474, Article 110474

2024

Volltextzugriff (PDF)

Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men

The journal of clinical endocrinology and metabolism, 2020-03, Vol.105 (3), p.e835-e847

2020

Volltextzugriff (PDF)

Efficacy, Safety, and Tolerability of a New Low-Dose Copper and Nitinol Intrauterine Device: Phase 2 Data to 36 Months

Obstetrics and gynecology (New York. 1953), 2020-04, Vol.135 (4), p.840-847

2020

Volltextzugriff (PDF)

Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorder

Journal of sexual medicine, 2024-09, Vol.21 (9), p.793-799

2024

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(38)
Tagungsberichte
(1)

Sprache

Englisch
(39)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials

A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial

PREGNANCIES BY ACTS OF INTERCOURSE WITH VAGINAL PH MODULATOR: RESULTS FROM THE AMPOWER STUDY

Characterization of Women Who Experienced Urinary Tract Infections in the Phase 3 AMPOWER Trial [A15]

Continuation rates of two different-sized copper intrauterine devices among nulliparous women: Interim 12-month results of a single-blind, randomised, multicentre trial

TIMING OF ON-STUDY PREGNANCIES WITH A VAGINAL pH MODULATOR IN THE PHASE 3 AMPOWER TRIAL

CHARACTERIZATION OF WOMEN ACCORDING TO THEIR SEXUAL SATISFACTION AFTER TREATMENT WITH THE NOVEL VAGINAL PH REGULATOR (VPR™) DURING THE AMPOWER STUDY

Genitourinary Side Effects With the Vaginal pH Regulator: Results From AMPOWER [19I]

Contraceptive efficacy should primarily be measured using life table pregnancy rates

Efficacy and safety of a multipurpose vaginal pH-regulator: results from the phase 3, ampower contraception clinical trial

Women’s satisfaction with the multipurpose vaginal pH-regulator (MVP-R; Amphora): results from the phase 3 ampower trial

Sexual Satisfaction Results With the Vaginal pH Modulator From the Phase 3 AMPOWER Study

Sexual Satisfaction Results with the Vaginal pH Modulator from the Phase 3 AMPOWER Study

Efficacy, Safety, and Acceptability of Acidform (Amphora) and Nonoxynol-9 Contraceptive Vaginal Gels [16N]

Perfect-Use Pregnancy Rates With the Vaginal pH Regulator: Efficacy Results From AMPOWER [30I]

Sexual Satisfaction With the Vaginal pH Regulator: Results From the AMPOWER Clinical Trial [32I]

Single-Dose, Bioadhesive Clindamycin 2% Gel for Bacterial Vaginosis: A Randomized Controlled Trial

Preliminary Efficacy of Topical Sildenafil Cream for the Treatment of Female Sexual Arousal Disorder: A Randomized Controlled Trial

Spherical Ball-Shaped Intrauterine Device Long-Acting Reversible Contraception: Post-marketing Pharmacovigilance Assessment

Successful Postcoital Testing of Ovaprene: An Investigational Non-hormonal Monthly Vaginal Contraceptive

The use of serum segesterone acetate levels to assess adherence of trial participants with a contraceptive vaginal ring

Emergency contraception for individuals weighing 80 kg or greater: A randomized trial of 30 mg ulipristal acetate and 1.5 mg or 3.0 mg levonorgestrel

Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men

Efficacy, Safety, and Tolerability of a New Low-Dose Copper and Nitinol Intrauterine Device: Phase 2 Data to 36 Months

Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorder

Suchergebnisse filtern